<DOC>
	<DOC>NCT00329940</DOC>
	<brief_summary>The purpose of this study is to assess rheumatologic tolerability of letrozole in postmenopausal patients with hormone receptor positive breast cancer having discontinued anastrozole adjuvant treatment due to musculoskeletal disorders.</brief_summary>
	<brief_title>Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal women receiving anastrozole adjuvant therapy for hormone receptor positive breast cancer who want to interrupt the treatment because of severe rheumatologic adverse events Polymorphonuclear neutrophils (PNN) ≥ 1200/mm3, platelets ≥ 100000/mm3, hemoglobin (Hb) ≥ 10 g/dL Bilirubin ≤ 30 μmol, SGOT/SGPT &lt; 3N Fully signed informed consent Pain due to bone fracture Metastatic disease Hormone therapy other than anastrozole Incapacitating or uncontrolled concomitant disease that could hamper patient's quality of life Hypersensitivity to letrozole or its components Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Letrozole</keyword>
	<keyword>breast cancer</keyword>
	<keyword>critical musculoskeletal</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>rheumatologic tolerance</keyword>
</DOC>